Progress in molecular and genetic studies of IgA nephropathy

Journal of Clinical Immunology

Volumn 21, Issue 5, 2001, Pages 310-327

  Novak, Jan ^a   Julian, Bruce A ^b   Tomana, Milan ^b   Mestecky, Jiri ^a  

^a University of California   (United States)

^b University of Alabama at Birmingham Heersink School of Medicine   (United States)

Author keywords

Aberrant glycosylation; IgA; IgA nephropathy; Immune complexes; O linked glycans

Indexed keywords

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; COMPLEX FORMATION; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FAILURE; MOLECULAR GENETICS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CHLORIDE CHANNELS; GALACTOSE; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; POLYSACCHARIDES;

EID: 0034753207     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012284402054     Document Type: Review

References (222)

1. Les depots intercapillaires d'IgA-IgG (Intercapillary deposits of IgA-IgG)
2. Worldwide perspective of IgA nephropathy
3. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?
4. The immunohistology of IgA nephropathy
5. Characteristics of eluted IgA in primary IgA nephropathy
6. Charge and size of mesangial IgA in IgA nephropathy
7. Biology of disease. IgA nephropathy: Pathogenesis of the most common form of glomerulonephritis
8. IgA nephropathy and Henoch-Schönlein syndrome
9. IgA nephropathy and related diseases
10. Analysis of charge distribution of lambda- and kappa-IgA in IgA nephropathy by focused antigen capture immunoassay
11. Charge distribution of IgA-lambda in IgA nephropathy
12. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis
13. IgA nephropathy
14. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients
15. Pathologic findings in mesangiopathic glomerulonephritis in Navajo Indians
16. Increased recognition of IgA nephropathy in African-American children
17. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors
18. IgA nephropathy: Presentation, clinical course, and prognosis in children and adults
19. Clinical features and natural history in adults with IgA nephropathy
20. Recurrent mesangial IgA nephritis following renal transplantation
21. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital
22. Repeat renal biopsy in children with IgA nephropathy
23. Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation
24. Evidence for genetic factors in the development and progression of IgA nephropathy
25. Increase of IgA-bearing peripheral blood lymphocytes in families of patients with IgA nephropathy
26. Immunological studies in a familial IgA nephropathy
27. Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy
28. Genetic factors in IgA nephropathy
29. Effects of sex hormones on mesangial cell proliferation and collagen synthesis
30. Estradiol suppresses mesangial cell type I collagen synthesis via activation of the MAP kinase cascade
31. Selective estrogen receptor modulators suppress mesangial cell collagen synthesis
32. Familial occurrence of primary glomerulonephritis: Evidence for a role of genetic factors
33. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23
34. Metabolic properties of human IgA subclasses
35. Mucosal immunoglobulins
36. Intravascular and mucosal immunoglobulin A: Two separate but related systems of immune defence?
37. Distribution of IgA1-, IgA2-, μ and J chain-containing cells in human tissues
38. Marked in vitro spontaneous secretion of IgA by human rib bone marrow mononuclear cells
39. Mesangial IgA in IgA nephropathy arises from the mucosa
40. Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: Evidence for the bone marrow as the source of mesangial IgA
41. Increased immunoglobulin A and immunoglobulin A1 cells in bone marrow trephine biopsy specimens in immunoglobulin A nephropathy
42. Elevation of IgA in IgA nephropathy is localized in the serum and not saliva and is restricted to the IgA1 subclass
43. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy
44. Comparative studies of the biological properties of human IgA subclasses
45. IgA subclasses
46. The sites of catabolism of murine monomeric IgA
47. Site of catabolism of autologous and heterologous IgA in non-human primates
48. Receptor-mediated binding and uptake of immunoglobulin A by human liver
49. IgA interactions with the asialoglycoprotein receptor
50. Analysis of the hepatobiliary transport of IgA with monoclonal anti-idiotype and anti-allotype antibodies
51. Carbohydrate-mediated clearance of secretory IgA from the circulation
52. Alteration in the IgA carbohydrate chains influence the cellular distribution of IgA1
53. IgA nephropathy (IgAN): A similarity in the mechanism of IgA1 deposition in the kidney in humans and mice
54. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes
55. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG
56. Galactose and N-acetylgalactosaminespecific endocytosis of glycopeptides by isolated rat hepatocytes
57. The carbohydrate composition of human myeloma IgA
58. The differences in carbohydrate composition between the subclasses of IgA immunoglobulins
59. Location and structural significance of the oligosaccharides in human IgA1 and IgA2 immunoglobulins
60. The human IgA system: A reassessment
61. O-linked oligosaccharides from human serum immunoglobulin A1
62. Structure of the carbohydrate units of IgA1 immunoglobulin II. Structure of the O-glycosidically linked oligosaccharide units
63. Carbohydrate heterogeneity of human IgA myeloma proteins of the IgA1 and IgA2 subclasses
64. Evidence for a site-specific fucosylation of N-linked oligosaccharide of immunoglobulin A1 from normal human serum
65. Phylogenetic development and comparative physiology of IgA
66. Partial duplication in the "hinge" region of IgA1 myeloma proteins
67. O-linked protein glycosylation structure and function
68. Why are proteins O-glycosylated?
69. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions
70. Structure of the human IgA subclasses and allotypes
71. Estimation of the number of O-linked oligosaccharides per heavy chain of human IgA1 by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) analysis of the hinge glycopeptide
72. Heterogeneity of O-glycosylation in the hinge region of human IgA1
73. Biosynthesis of truncated O-glycans in the T cell line Jurkat. Localization of O-glycan initiation
74. Pathways of O-glycan biosynthesis in cancer cells
75. Identification and characterization of large galactosyltransferase gene families: Galactosyltransferases for all functions
76. A family of human β3-galactosyltransferases. Characterization of four members of a UDP-galactose: β-N-acetyl-glucosamine/β-N-acetyl-galactosamine β-1,3-galactosyltransferase family
77. Cloning and expression of the GaI β1,3-GalNAc α2,3-sialyltransferase
78. Cloning and expression of a human gene encoding an N-acetylgalactosamine-α2,6-sialyltransferase (ST6GalNAc I): A candidate for synthesis of cancer-associated sialyl-Tn antigens
79. Molecular cloning and expression of GalNAc α2,6-sialyltransferase
80. Expression of core 2 β-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUCI tumor-associated epitopes
81. Differential expression of five sialyltransferase genes in human tissues
82. Human T-lymphocyte activation is associated with changes in O-glycan biosynthesis
83. Cell-specific expression of human β-galactoside α2,6-sialyltransferase transcripts differing in the 5′ untranslated region
84. Chromosome mapping and organization of the human β-galactoside α2,6-sialyltransferase gene. Differential and cell-type specific usage of upstream exon sequences in B-lymphoblastoid cells
85. Sialic acids. XIII. A uridine diphosphate D-galactose: Mucin galactosyltransferase from porcine submaxillary gland
86. Chintalacharuvu SR, Emancipator SN: The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines
87. Differential glycosylation of two glycoproteins synthesized by murine B cells in response to IL-4 plus IL-5
88. Hyperimmunization alters Fcγ antigenicity. Linkage to glycosylation
89. The effect on IgG glycosylation of altering β1,4-galactosyltransferase-I activity in B cells
90. Leucocyte β1,3 galactosyltransferase activity in IgA nephropathy
91. Glycobiology: More functions for oligosaccharides
92. A retrospective and prospective view of glycopathology
93. Biological roles of oligosaccharides: All of the theories are correct
94. Structural heterogeneity of glycans in immunoglobulin molecules: Implications in IgA nephropathy
95. Genetic remodeling of protein glycosylation in vivo induces autoimmune disease
96. Antibody production. Planning well ahead to meet future demand
97. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation
98. Searching for medicine's sweet spot
99. Glycosylation and immune system
100. Impairment of jacalin binding to serum IgA in IgA nephropathy
101. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy
102. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy
103. O-glycosylation of mesangial IgA1 in IgA nephropathy
104. MALDI-TOF MS analysis of glomerular IgA1 in IgA nephropathy (IgAN)
105. Study of the relationship between sticky human serum IgA1 and its O-glycan glycoform
106. Progress in the pathogenesis of IgA nephropathy
107. Structure of circulating immune complexes (CIC) in IgA nephropathy (IgAN)
108. Heterogeneity of carbohydrate moieties of IgA1 molecules from IgA nephropathy patients and normal individuals
109. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies
110. Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nepbropathy by mass spectrometry
111. The nucleotide sequence of the IgA1 hinge region in IgA nephropathy
112. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
113. Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry to the analysis of glycopeptide-containing multiple O-linked oligosaccharides
114. Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis
115. IgA glycosylation in IgA nephropathy
116. Pathogenesis of IgA nephropathy: Established observations, new insights and perspectives in treatment
117. Glomerulonephritis
118. O-linked oligosaccharide on IgA1 hinge region in IgA nephropathy. Fundamental study for precise structure and possible role
119. Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy
120. Abnormal glycosylation of IgA: Is it related to the pathogenesis of IgA nephropathy
121. Aberrant glycosylation of IgA from patients with IgA nephropathy
122. Increased sialylation of polymeric immunoglobulin A1: Mechanism of selective glomerular deposition in immunoglobulin A nephropathy?
123. IgA nephropathy: Recent developments
124. Exposed peptide core of IgA1 hinge region in IgA nephropathy
125. Humoral immunity against the proline-rich peptide epitope of the IgA1 hinge region in IgA nephropathy
126. Circulating immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schönlein nephritis. Correlation with clinical and histologic signs of activity
127. IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch-Schönlein nephritis
128. Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies
129. IgA containing circulating immune complexes in patients with IgA nephropathy
130. Immunoglobulin-antiimmunoglobulin interactions and immune complexes in IgA nephropathy
131. IgA immune complexes in Henoch-Schönlein purpura
132. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus
133. Characterization of circulating idiotypes containing immune complexes and their presence in the glomerular mesangium in patients with IgA nephropathy
134. Shared idiotypes in mesangial deposits in IgA nephropathy are not disease-specific
135. IgA myeloma presenting as Henoch-Schönlein purpura with nephritis
136. Deficient IgA1 galactosylation in children with idiopatic IgA nephropathy (IgAN) and Henoch Schönlein nephritis (HSPN)
137. Aggregated human serum immunoglobulin A1 induced by neuraminidase treatment had a lower number of O-linked sugar chains on the hinge portion
138. Evidence for involvement of IgA1 hinge glycopeptide in the IgA1-IgA1 interaction in IgA nephropathy
139. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins
140. Cellular distribution, regulation, and biochemical nature of an Fcα receptor in humans
141. Dysfunctions of Fcα receptors by blood phagocytic cells in IgA nephropathy
142. Down-regulation of Fcα receptors on blood cells of IgA nephropathy patients: Evidence for a negative regulatory role of serum IgA
143. Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89
144. Glycosylation of immunoglobulin A influences its receptor binding
145. Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound, IgA
146. The role of the carbohydrate chains in complement (C3) fixation by solid phase-bound human IgA
147. IgA antibody as a noninflammatory regulator of immunity
148. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy
149. Glomerular deposition of mannose-binding lectin in human glomerulonephritis
150. Aberrant synthesis of antibodies directed at the Fab of IgA in patients with IgA nephropathies
151. T cell clones with normal or defective O-galactosylation from a patient with permanent mixed-field polyagglutinability
152. Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome
153. Molecular basis of Tn-polyagglutinability
154. B lymphoblastoid cell lines with normal and defective O-glycosylation established from an individual with blood group Tn
155. Presence of the Tn antigen on hematopoietic progenitors from patients with the Tn syndrome
156. Persistent mixed-field polyagglutination
157. Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O-glycosylation
158. Epstein-Barr virus and its replication
159. O-linked oligosaccharides are acquired by herpes simplex glycoproteins in the Golgi apparatus
160. Structural and antigenic types of cell wall polysaccharides from viridans group streptococci with receptors for oral actinomyces and streptococcal lectins
161. A human immunoglobulin (Ig)A Cα3 domain motif directs polymeric Ig receptor-mediated secretion
162. Secretory component on epithelial cells is a surface receptor for polymeric immunoglobulins
163. Expression cloning of a human Fc receptor for IgA
164. Human hepatic lectin. Physicochemical properties and specificity
165. Fcα/μ receptor mediates endocytosis of IgM-coated microbes
166. IgA induced activation of human mesangial cells: Independent of FcαR1 (CD 89)
167. Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89)
168. Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells
169. Identification of a novel Fcα receptor expressed by mesangial cells
170. Human intestinal epithelial cells express a novel receptor for IgA
171. Interactions of cell-surface galactosyltransferase with immunoglobulins
172. Evidence for a specific IgA receptor in rat and human mesangial cells
173. Interaction of mesangial cells with IgA and IgG immune complexes: A possible mechanism of glomerular injury in IgA nephropathy
174. Mesangial cells possess an asialoglycoprotein receptor with affinity for human immunoglobulin A
175. Identification of a receptor on human mesangial cells specific for IgA1 hinge region glycans
176. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-α and IL-6, and proliferation
177. Interactions of human mesangial cells with IgA and IgA-containing circulating immune complexes
178. Sequence of human asialoglycoprotein receptor cDNA
179. Sequence of a second human asialoglycoprotein receptor: Conservation of two receptor genes during evolution
180. Proinflammatory cytokines regulate FcαR expression by human mesangial cells in vitro
181. Glomerular FcαR expression and disease activity in IgA nephropathy
182. Expression and physical association of Fcα receptor and Fc receptor γ chain in human mesangial cells
183. Identification of Fcα receptor (CD89) isoforms generated by alternative splicing that are differentially expressed between blood monocytes and alveolar macrophages
184. Fcα receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice
185. IgA nephropathy-specific expression of the IgA Fc receptors (CD89) on blood phagocytic cells
186. Interaction of IgA with Fcα receptors of human mesangial cells activates transcription factor nuclear factor-κB and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10
187. Intrinsic human glomerular mesangial cells can express receptors for IgG complexes (hFcγ RIII-A) and the associated Fcε RI γ-chain
188. Receptors for IgG complexes activate synthesis of monocyte chemoattractant peptide I and colony-stimulating factor 1
189. Regulation of Fc receptors for IgG on cultured rat mesangial cells
190. IFN-γ induces the high-affinity Fc receptor I for IgG (CD64) on humam glomerular mesangial cells
191. Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy
192. Combined glomerular deposition of polymeric rat IgA and IgG aggravates renal inflammation
193. Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: Loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus
194. Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21)
195. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor
196. Presence of the C3b complement receptor (CR1) antigen in the glomerular basement membrane of human fetal kidneys
197. Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines
198. Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney
199. Differential expression of complement C3 and C4 in the human kidney
200. Intraglomerular C3 synthesis in human kidney detected by in situ hybridization
201. Renal cortical complement C3 gene expression in IgA nephropathy
202. Antigen-antibody complexes enhance the production of complement component C3 by human mesangial cells
203. Immunohistochemical localization of C3d fragment of complement and S-protein (vitronectin) in normal and diseased human kidneys: Association with the C5b-9 complex and vitronectin receptor
204. Activation of glomerular mesangial cells by the terminal membrane attack complex of complement
205. Complement dependence of antibody-induced mesangial cell injury in the rat
206. Th1/Th2 predominance and proinflammatory cytokines determine clinicopathological severeity of IgA nephropathy
207. Receptors for immune complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: Role of TGF-β
208. Pathogenesis of IgA nephropathy: In vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion
209. Immune complexes bind to cultured rat glomerular mesangial cells to stimulate superoxide release. Evidence for an Fc receptor
210. Both IgG- and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells
211. Stimulation of Fcα receptors induces tyrosine phosphorylation of phospholipase C-γl, phosphatidylinositol phosphate hydrolysis, and Ca2+ mobilization in rat and human mesangial cells
212. Macrophage Fc receptor activity modulates mesangial cell proliferation and matrix synthesis
213. A specific Fcγ, receptor on cultured rat mesangial cells
214. The effect of IgA Immune complexes on the proliferation of cultured human mesangial cells
215. Potential factors governing extracellular matrix production by mesangial cells: Their relevance for the pathogenesis of IgA nephropathy
216. Pathogenic role of polyclonal and polymeric IgA in a murine model of mesangial proliferative glomerulonephritis with IgA deposition
217. Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6
218. Integrin expression and IgA nephropathy: In vitro modulation by IgA with altered glycosylation and macromolecular IgA
219. IgA and IgA Fc receptor
220. Fcα receptors